GlassScriptPhysician profile
John H Hendrick
NPI 1528021896
$10,810.58
in general payments reported to CMS, 2019-2025
36 companies · $2,558 in 2025
The $2,558 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $864 · 2022: $2,285 · 2023: $2,077 · 2024: $3,028 · 2025: $2,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,462 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,461.75 |
| Education | $200.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,329.00 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $1,126.92 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $699.23 | 2021-2025 | |
| Incyte Corporation | $689.73 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $678.96 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $659.81 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $606.34 | 2021-2025 | Ilumya, Winlevi, Odomzo |
| Galderma Laboratories, L.P. | $596.04 | 2022-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $582.05 | 2021-2025 | |
| Ucb, INC. | $535.44 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $463.91 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $355.99 | 2021-2025 | Dupixent, Libtayo |
| Almirall LLC | $309.45 | 2022-2025 | Klisyri, Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $297.80 | 2021-2022 | |
| Biofrontera INC. | $261.64 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $248.54 | 2022 | |
| Leo Pharma INC. | $207.59 | 2024-2025 | Adbry, Anzupgo |
| Janssen Scientific Affairs, LLC | $201.01 | 2021-2022 | |
| Amgen INC. | $194.27 | 2021-2025 | Otezla, Otezla, Enbrel |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $157.35 | 2023 | |
| Dermavant Sciences, INC. | $105.41 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $97.97 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Verrica Pharmaceuticals INC. | $59.29 | 2023-2024 | Ycanth |
| Organon LLC | $48.39 | 2025 | Vtama |
| Botanix Sb INC | $36.58 | 2025 | Sofdra |
| Lnhc, INC | $28.53 | 2025 | Zelsuvmi |
| Merz North America, INC. | $23.01 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.90 | 2025 | Spevigo |
| Smith+Nephew, INC. | $22.41 | 2023 | Grafix Pl |
| Paratek Pharmaceuticals, INC. | $19.35 | 2022 | |
| Epi Health, LLC | $18.38 | 2022 | |
| Sandoz INC. | $15.25 | 2025 | Hyrimoz |
| Strata Skin Sciences, INC. | $14.89 | 2024 | Xtrac |
| Bioventus LLC | $12.52 | 2022 | |
| Mayne Pharma Commercial LLC | $4.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.